Amphastar Pharmaceuticals’ (AMPH) “Hold” Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group reissued their hold rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage currently has a $22.00 price target on the stock, down from their prior price target of $30.00.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC lowered their price target on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Wells Fargo & Company lowered their price target on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Weiss Ratings cut shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Finally, Barclays lowered their price target on shares of Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $27.43.

Amphastar Pharmaceuticals Stock Down 7.5%

Shares of AMPH stock opened at $21.21 on Tuesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.90 and a current ratio of 4.02. The firm’s 50-day moving average is $22.01 and its 200-day moving average is $24.73. The stock has a market cap of $944.48 million, a price-to-earnings ratio of 10.45, a PEG ratio of 1.91 and a beta of 0.92. Amphastar Pharmaceuticals has a 52-week low of $17.03 and a 52-week high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, February 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.24). The firm had revenue of $183.11 million during the quarter, compared to the consensus estimate of $190.48 million. Amphastar Pharmaceuticals had a net margin of 13.63% and a return on equity of 17.58%. Sell-side analysts predict that Amphastar Pharmaceuticals will post 2.84 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Amphastar Pharmaceuticals by 24.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after buying an additional 435 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Amphastar Pharmaceuticals by 46.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after buying an additional 437 shares during the last quarter. ProShare Advisors LLC increased its stake in Amphastar Pharmaceuticals by 5.3% in the fourth quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock valued at $243,000 after purchasing an additional 457 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in Amphastar Pharmaceuticals by 2.4% in the fourth quarter. Los Angeles Capital Management LLC now owns 19,397 shares of the company’s stock valued at $478,000 after purchasing an additional 459 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Amphastar Pharmaceuticals by 37.8% in the fourth quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after purchasing an additional 462 shares in the last quarter. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.